Yasuhiro Setoguchi1, Shinyu Izumi2, Hidenori Nakamura3, Shigeo Hanada4, Kazuyoshi Marumo5, Atsuko Kurosaki6, Shouichi Akata7. 1. a 1 Tokyo Medical University, Department of Respiratory Medicine , 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan +81 333 426 111 ; +81 333 425 070 ; ystgc@tokyo-med.ac.jp. 2. b 2 National Center for Global Health and Medicine, Department of Respiratory Medicine , Tokyo, Japan. 3. c 3 Seirei Hamamatsu General Hospital, Department of Respiratory Medicine , Shizuoka, Japan. 4. d 4 Respiratory Center, Toranomon Hospital, Department of Respiratory Medicine , Tokyo, Japan. 5. e 5 Tokyo Metropolitan Police Hospital, Department of Internal Medicine , Tokyo, Japan. 6. f 6 Fukujuji Hospital, Department of Diagnostic Radiology , Tokyo, Japan. 7. g 7 Tokyo Medical University, Department of Radiology , Tokyo, Japan.
Abstract
OBJECTIVE: To investigate the potential beneficial effects of guideline-based pharmacological therapy on pulmonary function and quality of life (QOL) in Japanese chronic obstructive pulmonary disease (COPD) patients without prior treatment. RESEARCH DESIGN AND METHODS: Multicenter survey, open-label study of 49 Japanese COPD patients aged ≥ 40 years; outpatients with >10 pack years of smoking history; ratio of forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) < 70%; predicted FEV1 < 80%; treated with bronchodilators and/or inhaled corticosteroids as maintenance therapy until week 48. MAIN OUTCOME MEASURES: The primary endpoint was change in pulmonary function (trough FEV1, trough FVC); secondary endpoints were QOL and physical activity at 48 weeks after initiation of therapy. RESULTS: Airway reversibility was confirmed in untreated patients. Significant changes over time were not observed for FEV1 and FVC, indicating lung function at initiation of treatment was maintained during the observation period. COPD assessment test scores showed statistical and clinical improvements. Cough, sputum, breathlessness, and shortness of breath were significantly improved. CONCLUSIONS: Lung function and QOL of untreated Japanese COPD patients improved and improvements were maintained by performing a therapeutic intervention that conformed to published guidelines.
OBJECTIVE: To investigate the potential beneficial effects of guideline-based pharmacological therapy on pulmonary function and quality of life (QOL) in Japanese chronic obstructive pulmonary disease (COPD) patients without prior treatment. RESEARCH DESIGN AND METHODS: Multicenter survey, open-label study of 49 Japanese COPDpatients aged ≥ 40 years; outpatients with >10 pack years of smoking history; ratio of forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) < 70%; predicted FEV1 < 80%; treated with bronchodilators and/or inhaled corticosteroids as maintenance therapy until week 48. MAIN OUTCOME MEASURES: The primary endpoint was change in pulmonary function (trough FEV1, trough FVC); secondary endpoints were QOL and physical activity at 48 weeks after initiation of therapy. RESULTS: Airway reversibility was confirmed in untreated patients. Significant changes over time were not observed for FEV1 and FVC, indicating lung function at initiation of treatment was maintained during the observation period. COPD assessment test scores showed statistical and clinical improvements. Cough, sputum, breathlessness, and shortness of breath were significantly improved. CONCLUSIONS: Lung function and QOL of untreated Japanese COPDpatients improved and improvements were maintained by performing a therapeutic intervention that conformed to published guidelines.
Entities:
Keywords:
chronic obstructive pulmonary disease; chronic obstructive pulmonary disease assessment test; forced expiratory volume in 1 second; forced vital capacity; long-acting bronchodilators; quality of life
Authors: Dave Singh; Anthony D D'Urzo; James F Donohue; Edward M Kerwin; Eduard Molins; Ferran Chuecos; Anna Ribera; Diana Jarreta Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-12-06